Anke Schilhabel, PhD

University of Schleswig-Holstein, Campus Kiel, Germany

N/A

Poster(s):

• 1418 - A Refined Continuous Individualized Risk Index (CIRI2-CLL) for Accurately Predicting Outcomes after Limited-Duration CLL Therapy

• 1442 - NGS-based MRD assessment refines prognostication after venetoclax-based first-line combinations for chronic lymphocytic leukemia: A prospective analysis of the phase 3 GAIA/CLL13 trial